FLCCC Alliance issues open letter to UK researchers planning a new trial to test ivermectin for use in COVID-19

The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued an open letter to researchers  in England at the University of Oxford who are planning to conduct a double-blind, Randomized Controlled Trial (RCT) of ivermectin for use in COVID-19.  The letter states, “Our manuscript, which reviewed both epidemiologic data and the existing clinical trials evidence base, concluded that ivermectin should be the standard of care in COVID-19.”

• A meta-analysis of existing data of ivermectin as a therapeutic finds large, statistically significant reductions in time to clinical recovery, length of hospitalization, and death.
• The Declaration of Helsinki – Ethical Principles for Medical Research involving Human Subjects” states that “when combining medical research with medical care, patients can only be studied…if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.”

The full FLCCC open letter is HERE.                                                                         

Media: For further information or to arrange for an interview, please email [email protected].